CIK 0001752828 · <br>Emerging growth company
Celularity Inc
Sign in to watch- Ticker
- CELU
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831702591
- Phone
- (908) 768-2170
- Business address
- 170 PARK AVE, FLORHAM PARK, NJ, 07932
- Former names
- GX Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-16 | Hariri Robert J Chief Executive Officer | Grant or award · Stock Option Grant (Right to Buy) | +2,937,788 | 2,937,788 | ||
| 2024-02-16 | Kilcoyne Adrian Chief Medical Officer | Grant or award · Stock Option Grant (Right to Buy) | +205,213 | 205,213 | ||
| 2024-02-16 | Haines John R See Remarks | Grant or award · Stock Option Grant (Right to Buy) | +216,014 | 216,014 | ||
| 2024-02-16 | Beers David C Chief Financial Officer | Grant or award · Stock Option Grant (Right to Buy) | +183,612 | 183,612 | ||
| 2024-02-16 | Brigido Stephen Pres, Functional Regeneration | Grant or award · Stock Option Grant (Right to Buy) | +183,612 | 183,612 | ||
| 2024-02-16 | Fletcher Kyle See Remarks | Grant or award · Stock Option Grant (Right to Buy) | +164,171 | 164,171 | ||
| 2024-01-12 | Lim Kok Thay 10% owner | Purchase | +21,410,983 | $0.25 | $5.3M | 51,473,762 |
| 2024-01-12 | Lim Kok Thay 10% owner | Purchase · Warrants (Right to Buy) | +5,352,746 | $0.13 | $669K | 5,352,746 |
| 2024-01-12 | Lim Kok Thay 10% owner | Other disposition · Warrants (Right to Buy) | −6,529,818 | 0 | ||
| 2024-01-12 | Lim Kok Thay 10% owner | Other acquisition · Warrants (Right to Buy) | +6,529,818 | 6,529,818 | ||
| 2024-01-12 | Lim Kok Thay 10% owner | Purchase · Warrants (Right to Buy) | +16,500,000 | $0.13 | $2.1M | 16,500,000 |
| 2023-10-05 | Hariri Robert J Chief Executive Officer | Purchase | +6,307,158 | $0.16 | $1.0M | 25,520,007 |
| 2023-10-05 | Hariri Robert J Chief Executive Officer | Purchase | +3,050,427 | $0.16 | $484K | 28,570,434 |
| 2023-10-05 | Sorrento Therapeutics, Inc. 10% owner | Sale | −6,307,158 | 5,050,427 | ||
| 2023-09-29 | Hariri Robert J Chief Executive Officer | Purchase | +9,064,539 | $0.17 | $1.5M | 19,212,849 |
| 2023-09-29 | Sorrento Therapeutics, Inc. 10% owner | Sale | −9,064,539 | 11,357,585 | ||
| 2023-08-31 | Ling Geoffrey M.D. Director | Grant or award · Stock Option Grant (Right to Buy) | +1,250,000 | 1,250,000 | ||
| 2023-07-14 | Kilcoyne Adrian Chief Medical Officer | Grant or award | +875,000 | 1,175,000 | ||
| 2023-06-20 | Genting Berhad 10% owner | Purchase · Warrants (Right to Buy) | +3,000,000 | $0.13 | $375K | 3,000,000 |
| 2023-06-14 | Lim Kok Thay Director | Shares withheld for taxes | −10,844 | $0.75 | $8K | 225,222 |
Page 7 of 15 · 299 trades